克立硼罗软膏在皮肤科中的应用进展

doi:10.35541/cjd.20220709

Abstract

Abstract: 【Abstract】 Crisaborole ointment, a phosphodiesterase-4 inhibitor, has been approved for the treatment of mild to moderate atopic dermatitis in China. In addition, crisaborole has been reported for the successful treatment of other inflammatory skin disorders. This review summarizes mechanisms of action of crisaborole and its application to the treatment of atopic dermatitis, psoriasis, vitiligo, seborrheic dermatitis, inflammatory linear verrucous epidermal nevus, lichen simplex chronicus, prurigo pigmentosa, alopecia areata, plasma cell balanitis, and lichen planus.

Key words: Cyclic nucleotide phosphodiesterases, type 4, Phosphodiesterase-4 inhibitor, Crisaborole ointment, Skin diseases, Therapy, Dermatitis, atopic, Psoriasis, Vitiligo

Yang Siyan, Ma Lin, Zhang Bin. Application of crisaborole ointment in dermatology[J]. Chinese Journal of Dermatology, 2024, 57(10): 962-966.doi:10.35541/cjd.20220709

References ［40］

［1］	Chiricozzi A, Caposiena D, Garofalo V, et al. A new therapeutic for the treatment of moderate⁃to⁃severe plaque psoriasis: apremilast［J］. Expert Rev Clin Immunol, 2016,12（3）:237⁃249. doi: 10.1586/1744666X.2016.1134319.
［2］	Sakkas LI, Mavropoulos A, Bogdanos DP. Phosphodiesterase 4 inhibitors in immune⁃mediated diseases: mode of action, clinical applications, current and future perspectives［J］. Curr Med Chem, 2017,24（28）:3054⁃3067. doi: 10.2174/09298673246661 70530093902.
［3］	Page CP. Phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease［J］. Int Arch Allergy Immunol, 2014,165（3）:152⁃164. doi: 10.1159/000368800.
［4］	Jarnagin K, Chanda S, Coronado D, et al. Crisaborole topical ointment, 2%: a nonsteroidal, topical, anti⁃inflammatory phosphodiesterase 4 inhibitor in clinical development for the treatment of atopic dermatitis［J］. J Drugs Dermatol, 2016,15（4）:390⁃396.
［5］	中华医学会皮肤性病学分会免疫学组, 特应性皮炎协作研究中心. 中国特应性皮炎诊疗指南（2020版）［J］. 中华皮肤科杂志, 2020,53（2）:81⁃88. doi: 10.35541/cjd.20191000.
［6］	Bissonnette R, Pavel AB, Diaz A, et al. Crisaborole and atopic dermatitis skin biomarkers: an intrapatient randomized trial［J］. J Allergy Clin Immunol, 2019,144（5）:1274⁃1289. doi: 10.1016/j.jaci.2019.06.047.
［7］	Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 （PDE4） inhibitor for the topical treatment of atopic dermatitis （AD） in children and adults［J］. J Am Acad Dermatol, 2016,75（3）:494⁃503.e6. doi: 10.1016/j.jaad.2016.05.046.
［8］	Eichenfield LF, Call RS, Forsha DW, et al. Long⁃term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis［J］. J Am Acad Dermatol, 2017,77（4）:641⁃649.e5. doi: 10.1016/j.jaad.2017.06.010.
［9］	Schlessinger J, Shepard JS, Gower R, et al. Safety, effectiveness, and pharmacokinetics of crisaborole in infants aged 3 to < 24 months with mild⁃to⁃moderate atopic dermatitis: a phaseⅣopen⁃label study （CrisADe CARE 1）［J］. Am J Clin Dermatol, 2020,21（2）:275⁃284. doi: 10.1007/s40257⁃020⁃00510⁃6.
［10］	Pao⁃Ling Lin C, Gordon S, Her MJ, et al. A retrospective study: application site pain with the use of crisaborole, a topical phosphodiesterase 4 inhibitor［J］. J Am Acad Dermatol, 2019,80（5）:1451⁃1453. doi: 10.1016/j.jaad.2018.10.054.
［11］	Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 （PDE4） inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phaseⅢ, randomized, controlled trial （Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis ［ESTEEM］ 1）［J］. J Am Acad Dermatol, 2015,73（1）:37⁃49. doi: 10.1016/j.jaad.2015.03.049.
［12］	Liu Y, Li W. Crisaborole ointment as treatment for genital psoriasis［J］. J Cosmet Dermatol, 2022,21（9）:4080⁃4081. doi: 10.1111/jocd.14706.
［13］	Lee EB, Lebwohl MG, Wu JJ. Treatment of psoriasis with crisaborole［J］. J Dermatolog Treat, 2019,30（2）:156⁃157. doi: 10.1080/09546634.2018.1480747.
［14］	Liu Y, Li W. Successful treatment with crisaborole for facial lesions refractory to adalimumab in a man with psoriasis: a case report［J］. Dermatol Ther, 2022,35（5）:e15424. doi: 10.1111/dth.15424.
［15］	Hashim PW, Chima M, Kim HJ, et al. Crisaborole 2% ointment for the treatment of intertriginous, anogenital, and facial psoriasis: a double⁃blind, randomized, vehicle⁃controlled trial［J］. J Am Acad Dermatol, 2020,82（2）:360⁃365. doi: 10.1016/j.jaad.2019.06.1288.
［16］	Robbins AB, Gor A, Bui MR. Topical crisaborole⁃a potential treatment for recalcitrant palmoplantar psoriasis［J］. JAMA Dermatol, 2018,154（9）:1096⁃1097. doi: 10.1001/jamadermatol. 2018.2397.
［17］	Majid I, Imran S, Batool S. Apremilast is effective in controlling the progression of adult vitiligo: a case series［J］. Dermatol Ther, 2019,32（4）:e12923. doi: 10.1111/dth.12923.
［18］	Tam I, Kahn JS, Rosmarin D. Repigmentation in a patient with vitiligo on crisaborole 2% ointment［J］. JAAD Case Rep, 2021,11:99⁃101. doi: 10.1016/j.jdcr.2021.03.028.
［19］	Sun X, Sheng A, Xu AE. Successful treatment of vitiligo with crisaborole ointment: a report of two cases［J］. Br J Dermatol, 2023,188（3）:436⁃437. doi: 10.1093/bjd/ljac092.
［20］	Li J, Feng Y, Liu C, et al. Presence of Malassezia hyphae is correlated with pathogenesis of seborrheic dermatitis［J］. Microbiol Spectr, 2022,10（1）:e0116921. doi: 10.1128/spectrum. 01169⁃21.
［21］	Liu D, Chow P, Strawn S, et al. Chronic nasolabial fold seborrheic dermatitis successfully controlled with crisaborole［J］. J Drugs Dermatol, 2018,17（5）:577⁃578.
［22］	Peña SM, Oak A, Smith AM, et al. Topical crisaborole is an efficacious steroid⁃sparing agent for treating mild⁃to⁃moderate seborrhoeic dermatitis［J］. J Eur Acad Dermatol Venereol, 2020,34（12）:e809⁃e812. doi: 10.1111/jdv.16673.
［23］	Ossorio⁃García L, Jiménez⁃Gallo D, Collantes⁃Rodríguez C, et al. Treatment of inflammatory linear verrucous epidermal nevus pruritus with thalidomide［J］. J Dtsch Dermatol Ges, 2018,16（9）:1141⁃1142. doi: 10.1111/ddg.13628.
［24］	Barney E, Prose NS, Ramirez M. Inflammatory linear verrucous epidermal nevus treated successfully with crisaborole ointment in a 5⁃year⁃old boy［J］. Pediatr Dermatol, 2019,36（3）:404⁃405. doi: 10.1111/pde.13793.
［25］	Altunay İK, Özkur E, Uğurer E, et al. More than a skin disease: stress, depression, anxiety levels, and serum neurotrophins in lichen simplex chronicus［J］. An Bras Dermatol, 2021,96（6）:700⁃705. doi: 10.1016/j.abd.2021.04.011.
［26］	Wei G, Rodriguez⁃Waitkus P, Soylu L. A rare case of lichen simplex chronicus in an adolescent female successfully managed with crisaborole［J］. Dermatol Ther, 2021,34（2）:e14752. doi: 10.1111/dth.14752.
［27］	Zeng X, Li L, Cui BN. Prurigo pigmentosa: a clinical and histopathological study of nine Chinese cases［J］. J Eur Acad Dermatol Venereol, 2016,30（10）:1794⁃1798. doi: 10.1111/jdv. 13659.
［28］	Mufti A, Mirali S, Abduelmula A, et al. Clinical manifestations and treatment outcomes in prurigo pigmentosa （Nagashima disease）: a systematic review of the literature［J］. JAAD Int, 2021,3:79⁃87. doi: 10.1016/j.jdin.2021.03.003.
［29］	Xu M, Wu N, Du Q, et al. Crisaborole: an emerging therapy for prurigo pigmentosa［J］. J Eur Acad Dermatol Venereol, 2022,36（6）:e441⁃e443. doi: 10.1111/jdv.17938.
［30］	Lu PH, Hui RC, Yang LC, et al. Prurigo pigmentosa: a clinicopathological study and analysis of associated factors［J］. Int J Dermatol, 2011,50（1）:36⁃43. doi: 10.1111/j.1365⁃4632. 2010.04625.x.
［31］	Zhang X, Zhao Y, Ye Y, et al. Lesional infiltration of mast cells, Langerhans cells, T cells and local cytokine profiles in alopecia areata［J］. Arch Dermatol Res, 2015,307（4）:319⁃331. doi: 10. 1007/s00403⁃015⁃1539⁃1.
［32］	Suárez⁃Fariñas M, Ungar B, Noda S, et al. Alopecia areata profiling shows TH1, TH2, and IL⁃23 cytokine activation without parallel TH17/TH22 skewing［J］. J Allergy Clin Immunol, 2015,136（5）:1277⁃1287. doi: 10.1016/j.jaci.2015.06.032.
［33］	Avitabile S, Sordi D, Garcovich S, et al. Effective squaric acid dibutylester immunotherapy is associated with a reduction of skin infiltrating T⁃helper （Th）1 and Th17 cells in alopecia areata patients［J］. J Dermatol, 2015,42（1）:98⁃99. doi: 10.1111/1346⁃8138.12740.
［34］	Taneja N, Gupta S. Apremilast is efficacious in refractory alopecia areata［J］. J Dermatolog Treat, 2020,31（7）:727⁃729. doi: 10.1080/09546634.2019.1616046.
［35］	张帆, 糜自豪, 孙勇虎. 外用磷酸二酯酶4抑制剂软膏治疗斑秃一例附文献复习［J］. 中国麻风皮肤病杂志, 2022,38（4）:217⁃219. doi: 10.12144 /zgmfskin202204217
［36］	Serrão LM, Sarmenghi KDA, Pinto BCBP, et al. Thalidomide in plasma cell balanitis refractory to conventional topical treatment［J］. An Bras Dermatol, 2018,93（6）:881⁃883. doi:10.1590/abd1806⁃4841.20187462.
［37］	Piaserico S, Orlando G, Linder MD, et al. A case⁃control study of risk factors associated with Zoon balanitis in men［J］. J Eur Acad Dermatol Venereol, 2019,33（8）:1591⁃1594. doi: 10.1111/jdv.15594.
［38］	Niu X, Yang X, Wang F, et al. A novel and effective therapy for Zoon balanitis: topical crisaborole 2% ointment［J］. J Eur Acad Dermatol Venereol, 2023,37（2）:e212⁃e214. doi: 10.1111/jdv. 18494.
［39］	Solimani F, Forchhammer S, Schloegl A, et al. Lichen planus ⁃ a clinical guide［J］. J Dtsch Dermatol Ges, 2021,19（6）:864⁃882. doi: 10.1111/ddg.14565.
［40］	Lu H, He R, Yang S, et al. Successful treatment of pediatric lichen planus with topical Crisaborole［J］. Dermatol Ther, 2022,35（12）:e15893. doi: 10.1111/dth.15893.

[1]	Wang Ruixia, Qu Yanlei, Ai Wenjin, Yan Lin, Qu Caijie, Shi Tongxin. A case of nonbullous neutrophilic lupus erythematosus [J]. Chinese Journal of Dermatology, 2024, 57(9): 832-834.
[2]	Zhang Jiaqi, Wu Fan, Han Yuqing, Liu Qi, Pan Yao. Application of multi-photon microscopy in dermatology [J]. Chinese Journal of Dermatology, 2024, 57(9): 857-862.
[3]	Hao Feng, Liu Guoyan. Application of optical coherence tomography in dermatology [J]. Chinese Journal of Dermatology, 2024, 57(9): 853-857.
[4]	Zou Xianbiao, Chen Jinchun, Zeng Yue, Hao Yi. Application of ultrasonography in dermatology: progress and prospects [J]. Chinese Journal of Dermatology, 2024, 57(9): 785-790.
[5]	Xiang Xi, Zhang Lingyan, Zhong Lin, Gao Yi, Qiu Li. Multimodal ultrasound manifestations of port-wine stains and their application in efficacy assessment of photodynamic therapy [J]. Chinese Journal of Dermatology, 2024, 57(9): 801-806.
[6]	Zeng Yue, Shao Huihong, Lin Shiwen, Wen Rou, Zou Xianbiao. Application of a wearable teleconsultation device in diagnosis of common skin diseases [J]. Chinese Journal of Dermatology, 2024, 57(9): 797-800.
[7]	Qiao Jiaxi, Xia Ping, Chen Liuqing. Analysis of dermoscopic and reflectance confocal microscopic features of psoriatic lesions before and after treatment with secukinumab [J]. Chinese Journal of Dermatology, 2024, 57(9): 825-829.
[8]	Wei-Qi REN Ya-Ru ZOU Min PAN. Risk factors for secondary infection in patients with bullous pemphigoid [J]. Chinese Journal of Dermatology, 2024, 57(8): 770-772.
[9]	Lin Ziyuan, Pang Tianyi, Wu Jingwen, Jin Hui, . Role of polycyclic aromatic hydrocarbons in the occurrence and development of inflammatory skin diseases [J]. Chinese Journal of Dermatology, 2024, 57(8): 765-769.
[10]	Luo Li, Zhang Bona, Wu Wei, Tang Wenjing, Li Yuehua, Liu Xiaoli, Ma Yanan, Li Cuicui, Qi Mengyan, Sun Ni, Shi Qiong. Efficacy and safety of 308-nm excimer laser and 308-nm excimer lamp in the treatment of 194 children with vitiligo: a retrospective study [J]. Chinese Journal of Dermatology, 2024, 57(8): 721-727.
[11]	Dou Jinfa, Wang Jianbo, Zhang Shuai, Li Jianguo, Liu Hongwei, Zhang Shoumin. Analysis of changes in disease status and their influencing factors in patients with moderate to severe plaque psoriasis receiving biologic therapy during the coronavirus disease 2019 pandemic: a single-center cross-sectional study [J]. Chinese Journal of Dermatology, 2024, 57(8): 739-742.
[12]	Chen Haotian, Liu Lian, Zhang Ting, Liu Qingfeng, Li Xiaoxue, Diao Ping, Jiang Xian. Port-wine stains: mechanisms underlying the development and progression [J]. Chinese Journal of Dermatology, 2024, 57(7): 661-664.
[13]	Diao Ping, Han Chenglong, Liu Lian, Zhou Hui, Li Erlong, Jiang Xian. Efficacy and influencing factors of hematoporphyrin monomethyl ether-mediated photodynamic therapy in the treatment of adult patients with port-wine stains: a retrospective study [J]. Chinese Journal of Dermatology, 2024, 57(7): 595-600.
[14]	Zhang Sheng, Wang Xiuwei, Chen Jianyou, Deng Wei, Zhang Haihua, Zhang Gaolei, Liu Xiaoyan, Su Wei. Efficacy of hematoporphyrin monomethyl ether-mediated photodynamic therapy in the treatment of facial port-wine stains in 15 children with Sturge-Weber syndrome [J]. Chinese Journal of Dermatology, 2024, 57(7): 616-622.
[15]	Jiang Xian, Liu Lian, Zhang Ting. Treatment of port-wine stains: current status and prospects [J]. Chinese Journal of Dermatology, 2024, 57(7): 590-594.

Application of crisaborole ointment in dermatology

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［40］

Related Articles 15

Metrics

Comments

Recommended 10